Cefazolin

DRUG NAME: Cefazolin

1. Surgical prophylaxis — Cefazolin is the single most widely used antibiotic for surgical prophylaxis in India and globally. It is the standard of care for clean and clean-contaminated surgical procedures across orthopaedics, cardiac surgery, general surgery, gynaecology, and neurosurgery. Its long half-life (~1.8–2.5 hours), excellent tissue penetration, antistaphylococcal + limited gram-negative activity, low adverse effect profile, and q4h intraoperative re-dosing interval make it the optimal perioperative prophylactic agent.
2. MSSA infections — an emerging first-line alternative to antistaphylococcal penicillins — The landmark FIRST trial (Tong et al., JAMA 2023, n=1491) demonstrated that IV cefazolin was non-inferior to IV antistaphylococcal penicillins (nafcillin/oxacillin/cloxacillin/flucloxacillin) for MSSA bacteraemia. This has significantly elevated cefazolin’s role from ”alternative agent“ to a legitimate first-line option for serious MSSA infections — with major practical advantages: q8h dosing (vs q4–6h for antistaphylococcal penicillins), lower phlebitis rate, lower hepatotoxicity, lower interstitial nephritis risk, and NLEM availability.
3. Penicillin allergy bridge — Cefazolin is the most important cephalosporin alternative for patients with non-severe penicillin allergy who need antistaphylococcal therapy. Cross-reactivity between penicillins and cefazolin is ~2–5% (primarily for non-anaphylactic reactions) — making it usable in the vast majority of penicillin-allergic patients with appropriate monitoring.

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• Intravenous (IV) — slow IV injection (bolus) or intermittent IV infusion (primary and preferred route)
• Intramuscular (IM) — deep IM injection (acceptable alternative when IV access is unavailable; used in outpatient and OPAT settings)

---

Biosimilar Status:

---

Formulations Available in India

• Capsules: 250 mg, 500 mg
• Dry syrup: 125 mg/5 mL, 250 mg/5 mL
• Dispersible tablets available from some manufacturers
• Widely available across India

---

PHARMACOKINETICS

---

---

---

---

---

ADULT INDICATIONS + DOSING

---

• Starting dose: Full therapeutic dose from first administration (no titration for antibiotics)
• Titration: Not applicable
• Usual maintenance dose: 2 g IV q8h for serious MSSA infections; 1–2 g IV single dose for prophylaxis
• Maximum dose: Max 2 g per dose; Max 8 g per day (q6h dosing)

---

Primary Indications (Approved / Standard in India)

---

1. When to prefer cefazolin over alternatives: ✅ Cefazolin is the undisputed first-line surgical prophylaxis agent for clean and clean-contaminated surgery. Its advantages over alternatives are: excellent bone/tissue penetration, long half-life (q4h re-dosing — less frequent than any penicillin), broad enough spectrum for SSI pathogens (MSSA + streptococci + limited gram-negatives), low adverse effect profile, and low cost (NLEM, price-controlled).
2. When NOT to use: ⛔ Do NOT use cefazolin alone for procedures involving bowel (colorectal surgery — add metronidazole). ⛔ Do NOT use cefazolin for MRSA-colonised patients as sole prophylactic agent — add vancomycin. ⛔ Do NOT use in patients with confirmed severe penicillin/cephalosporin anaphylaxis — use vancomycin ± aminoglycoside (or clindamycin) as alternative prophylaxis per AIIMS protocol. ⛔ Do NOT continue prophylaxis >24 hours post-operatively.
3. NLEM India status: ✅ Cefazolin injection 1 g IS included in NLEM India 2022 — specifically listed for surgical prophylaxis. This makes it available through government supply chains and at subsidised rates.
4. Time to expected benefit: Tissue levels are achieved within 30–60 minutes of IV administration — this defines the mandatory timing of ”within 60 minutes before incision.“
5. Treatment failure (SSI despite prophylaxis): If SSI develops despite appropriate prophylaxis → obtain wound culture. Common causes of prophylaxis failure: (a) timing error (administered too early or too late); (b) failure to re-dose intraoperatively; © MRSA infection (not covered by cefazolin); (d) gram-negative/anaerobic SSI (may need broader coverage for contaminated procedures); (e) patient-related factors (diabetes, obesity, immunosuppression, malnutrition).
6. Baseline investigations: MANDATORY: Allergy history (penicillin/cephalosporin allergy check). RECOMMENDED: Renal function (dose adjustment if CrCl <30 mL/min — for the rare patient with CKD undergoing surgery). OPTIONAL: Pre-operative wound culture (if pre-existing infection or colonisation with resistant organism suspected).
7. Specialist initiation: ✅ Not required — surgical prophylaxis with cefazolin is standard across all surgical specialities and should be administered by the anaesthetist or surgeon. Every surgical team should have a written prophylaxis protocol posted in the OT.
8. Indian guideline source: API Textbook of Medicine (Surgical Infections chapter); AIIMS Surgical Prophylaxis Protocol; NCDC Infection Control Guidelines; ASHP/IDSA/SIS Surgical Prophylaxis Guidelines 2013 (widely adopted in Indian surgical practice).
9. Key safety warning: ⚠️ Prolonged prophylaxis (>24 hours) is the single most common surgical antibiotic prescribing error in India. Across Indian hospitals, prophylactic antibiotics are routinely continued for 3–7 days post-operatively — despite decades of evidence showing NO benefit and increased harm (CDI, AMR, adverse effects, cost). Active antimicrobial stewardship programmes should target this practice.
10. Dose adjustment: ⚠️ Obese patients require higher doses — 2 g for patients 80–119 kg; 3 g for patients ≥120 kg. Failure to weight-adjust is a common cause of subtherapeutic tissue levels and SSI in obese patients.

---

• Persistent positive blood cultures >72 hours
• Endocarditis (modified Duke criteria)
• Metastatic foci (osteomyelitis, septic arthritis, epidural/splenic/psoas abscess)
• Prosthetic material (prosthetic valve, joint, vascular graft, pacemaker)
• Injection drug use as source

1. When to prefer cefazolin over cloxacillin for MSSA bacteraemia:
2. • ✅ FIRST trial data (2023): Non-inferiority of cefazolin vs antistaphylococcal penicillins established in the largest RCT ever conducted for MSSA bacteraemia (n=1491). Cefazolin offers:
   • • q8h dosing (3 doses/day) vs q4–6h (4–6 doses/day) → 50% reduction in nursing workload
     • Lower phlebitis → fewer painful IV site changes, fewer PICC insertions
     • No hepatotoxicity → no need for weekly LFT monitoring (unlike oxacillin)
     • No CYP3A4 induction → no warfarin/cyclosporine/voriconazole interaction (unlike nafcillin/dicloxacillin)
     • No interstitial nephritis → no weekly creatinine surveillance specifically for this ADR (unlike nafcillin)
     • ✅ NLEM-listed, widely available, affordable
   • ✅ Preferred in specific patient groups:
   • • Patients on warfarin/acenocoumarol (no CYP interaction)
     • Transplant patients on cyclosporine/tacrolimus (no CYP interaction)
     • Patients with pre-existing liver disease (no hepatic metabolism, no hepatotoxicity)
     • Elderly patients (fewer daily doses, lower ADR burden)
     • Resource-limited settings (fewer injections/day = lower nursing/consumable cost)
3. When to prefer cloxacillin OVER cefazolin:
4. • ℹ️ Some Indian ID experts still prefer IV cloxacillin for:
   • • Very high-inoculum infections (large vegetations in endocarditis, undrained large abscesses) — theoretical inoculum effect concern (though FIRST trial largely refuted clinical significance)
     • Prosthetic valve endocarditis — FIRST trial did not specifically power for PVE subgroup analysis; some experts remain cautious
     • MSSA isolates with documented high inoculum-effect MIC (if laboratory performs this specialised test — very rare in India)
   • ℹ️ API Textbook recommends antistaphylococcal penicillins as first-line; AIIMS ID protocol is increasingly adopting cefazolin as co-first-line — both approaches are acceptable in 2025 Indian practice.
5. NLEM India: ✅ Cefazolin injection IS NLEM-listed.
6. Time to response: Blood cultures should become negative within 48–96 hours. Defervescence within 48–72 hours. Repeat blood cultures at 48–72 hours — MANDATORY.
7. Treatment failure: Persistent positive cultures at >72 hours → investigate: undrained source, endocarditis, metastatic infection, resistant organism (reconfirm MSSA). Consider adding rifampicin (if prosthetic material) or switching to daptomycin. Specialist (ID) involvement mandatory.
8. Baseline investigations:
9. • MANDATORY: Blood cultures ×2 sets, allergy history, serum creatinine (renal dose adjustment may be needed), echocardiography (TTE for ALL SAB; TEE if complicated)
   • RECOMMENDED: CBC, CRP/procalcitonin, LFTs (baseline comparison), urinalysis
10. Specialist initiation: ⚠️ RECOMMENDED — ID consultation for ALL S. aureus bacteraemia.
11. Indian guideline: API Textbook (Staphylococcal Infections); ICMR AMR Guidelines 2019; AIIMS Empiric Antibiotic Protocol; FIRST trial (Tong et al., JAMA 2023).
12. Key safety warning: ⚠️ Renal dose adjustment IS required for cefazolin (unlike nafcillin which is hepatically cleared). In patients with CrCl <30 mL/min: extend interval to q12h. In HD patients: give supplemental dose post-dialysis. See Renal Adjustment (Part 3).
13. Dose adjustment: Renal impairment — see Renal Adjustment. Obesity — use 2 g dose (standard for serious infections; no additional obesity adjustment beyond the 2 g dose for treatment indications). ARC — consider q6h dosing.

---

1. FIRST trial context: The FIRST trial included patients with endocarditis and showed non-inferior outcomes with cefazolin. ESC 2023 Endocarditis Guidelines now include cefazolin as an accepted option for MSSA NVE.
2. Inoculum effect concern for endocarditis: Some experts remain cautious about cefazolin for endocarditis with large vegetations (high bacterial density → potential inoculum effect). For such cases: some ID specialists prefer cloxacillin/flucloxacillin or use cefazolin at q6h dosing (2 g q6h = 8 g/day — approaching maximum dose) to overcome the inoculum effect with higher free drug levels.
3. Oral step-down (POET trial): After ≥10 days of IV therapy for uncomplicated left-sided endocarditis, switch to oral cephalexin 1 g q6h (or oral cloxacillin/dicloxacillin 1 g q6h) to complete course.
4. NLEM India: ✅ Cefazolin IS NLEM.
5. Specialist initiation: ⚠️ MANDATORY — cardiologist + ID specialist.
6. Indian guideline: API Textbook (Endocarditis chapter); CSI recommendations; AHA/IDSA Endocarditis Guidelines 2015; POET trial; FIRST trial.

---

1. When to prefer cefazolin: ✅ Culture-confirmed MSSA osteomyelitis — cefazolin 2 g IV q8h offers excellent bone penetration (bone:serum ratio ~15–30% — one of the highest among beta-lactams), combined with practical dosing advantages over cloxacillin (q8h vs q4–6h). OVIVA trial (2019) supports oral step-down after initial IV phase.
2. Cefazolin advantage for osteomyelitis: The longer half-life means bone tissue concentrations remain above MIC for a larger fraction of the dosing interval compared to shorter half-life penicillins.
3. NLEM India: ✅ Cefazolin IS NLEM. Cephalexin (oral step-down) ✅ also NLEM.
4. ⚠️ India-specific: Always consider TB osteomyelitis — particularly vertebral (Pott’s spine), hip, and knee. Obtain tissue for GeneXpert, AFB culture, histopathology.
5. Baseline investigations: MANDATORY: Bone/tissue culture (intraoperative ideally), blood cultures, CRP, ESR, imaging (X-ray ± MRI), renal function (for cefazolin dose adjustment).
6. Specialist initiation: ⚠️ MANDATORY — orthopaedic surgeon + ID specialist.

---

1. Joint drainage (arthroscopic washout or serial aspiration) is MANDATORY — antibiotics alone are insufficient.
2. NLEM: ✅ Both cefazolin and cephalexin are NLEM.
3. Indian guideline: API Textbook; AIIMS Orthopaedic Protocol.

---

1. When to prefer cefazolin for SSTIs:
2. • ✅ Moderate-severe MSSA SSTI requiring IV therapy — cefazolin offers q8h dosing, low phlebitis, and seamless step-down to oral cephalexin (same generation).
   • ✅ Also covers some community-acquired gram-negative organisms (E. coli, Proteus) — useful when SSTI is at an anatomical site prone to gram-negative involvement (perineal, lower extremity with venous stasis ulceration).
3. When NOT to use:
4. • ⛔ MRSA SSTI — use cotrimoxazole, doxycycline, clindamycin, or vancomycin per severity.
   • ⛔ Polymicrobial SSTI with anaerobic involvement (bite wounds, diabetic foot, perianal) — add metronidazole or use ampicillin-sulbactam/amoxicillin-clavulanate.
   • ⛔ Necrotising fasciitis — broad-spectrum coverage needed (clindamycin + piperacillin-tazobactam/carbapenem ± vancomycin).
   • ⛔ Mild SSTI manageable with oral therapy — use oral cephalexin directly (no need for IV cefazolin).
5. NLEM India: ✅ Both cefazolin (IV) and cephalexin (oral) are NLEM.
6. IV-to-oral step-down: Afebrile ≥48 hours, cellulitis regressing, no bacteraemia, tolerating oral intake → switch to oral cephalexin 500 mg q6–8h.
7. Indian guideline: API Textbook; ICMR AMR Guidelines 2019; IADVL Guidelines.

---

1. When to prefer: Cefazolin IV is appropriate for hospitalised pyelonephritis or complicated UTI when urine culture confirms a susceptible, non-ESBL gram-negative organism (E. coli, Proteus mirabilis, Klebsiella — non-ESBL). Also provides concomitant staphylococcal coverage if concurrent SSTI or catheter-site infection.
2. ⚠️ CRITICAL India-specific limitation: ESBL prevalence among Indian uropathogens (especially E. coli and Klebsiella) is 40–70% in hospital-acquired UTIs. Cefazolin is completely ineffective against ESBL producers. Do NOT use cefazolin as empiric therapy for nosocomial UTI in India without culture guidance. For empiric therapy of complicated/nosocomial UTI: use piperacillin-tazobactam, ceftriaxone (if local susceptibility supports), or carbapenems based on institutional antibiogram.
3. When it IS reasonable for empiric use: Community-acquired, uncomplicated pyelonephritis in a young woman without prior antibiotic exposure, no healthcare contact, and no known risk factors for ESBL carriage — cefazolin may be used empirically pending culture. However, in most Indian urban settings, even community-acquired E. coli ESBL rates exceed 20–30% — clinical judgment and local antibiogram are essential.
4. NLEM India: ✅ Cefazolin IS NLEM.
5. Baseline investigations: MANDATORY: Urine culture and sensitivity BEFORE starting. Renal function (dose adjustment needed if CrCl <30). Blood cultures if systemic sepsis suspected.
6. Indian guideline: API Textbook (UTI chapter); ICMR AMR Guidelines 2019.

---

1. Context: First-line GBS IAP is IV Penicillin G (5 million units loading, then 2.5–3 million units q4h until delivery) or IV Ampicillin (2 g loading, then 1 g q4h until delivery). Cefazolin is the first-line alternative for penicillin-allergic patients with NON-SEVERE allergy (rash, mild urticaria — NOT anaphylaxis, angioedema, or bronchospasm).
2. When to use cefazolin for GBS IAP: Patient with documented mild penicillin allergy (non-IgE mediated) who is GBS-positive or has GBS IAP indication. Penicillin-cephalosporin cross-reactivity at ~2–5% — acceptable risk for non-anaphylactic prior reactions with monitored first dose.
3. When NOT to use: ⛔ If patient has history of severe penicillin anaphylaxis — use clindamycin (if GBS isolate is clindamycin-susceptible) or vancomycin (if clindamycin-resistant or susceptibility unknown). Do NOT use cefazolin if prior anaphylaxis to penicillin or cephalosporin.
4. NLEM India: ✅ Cefazolin IS NLEM.
5. Indian guideline: FOGSI Guidelines; API Textbook (Obstetric Infections); CDC GBS Prevention Guidelines (adapted for Indian practice).

---

Secondary Indications — Adults Only (Off-label, if any)

---

• 💡 Cefazolin is the IDEAL antibiotic for OPAT among antistaphylococcal agents because:
• • q8h dosing = 3 injections/day (vs 6 for nafcillin q4h or 4–6 for cloxacillin q4–6h) — feasible for patient/caregiver self-administration or home nursing visits
  • Excellent stability after reconstitution (see Part 3) — allows pre-preparation of doses
  • Low phlebitis rate — tolerable via peripheral or PICC IV
  • IM route is well-absorbed and acceptable for some OPAT protocols (reduces need for IV access maintenance)
  • Good safety profile — low monitoring burden (renal function only; no LFTs, no TDM)
• ⚠️ India-specific OPAT context: OPAT is an emerging practice in India — available primarily at select tertiary centres in major metros (AIIMS, CMC Vellore, select corporate hospitals). Most Indian patients requiring prolonged IV antibiotics remain hospitalised. Promoting cefazolin-based OPAT in India could significantly reduce hospitalisation duration, healthcare costs, and nosocomial infection risk.
• Evidence basis:Moderate — IDSA OPAT Guidelines; Indian observational OPAT experience from select centres.

---

• ⚠️ Specialist only — nephrologist supervision. PD peritonitis is managed per ISPD guidelines adopted by the Indian Society of Nephrology.
• Empiric therapy covers both gram-positive (cefazolin IP) and gram-negative (gentamicin or ceftazidime IP) until culture results guide targeted therapy.
• ℹ️ Intraperitoneal administration route is the primary route for PD peritonitis — NOT IV.
• Evidence basis:Strong — ISPD Peritonitis Guidelines (2022); Indian Society of Nephrology recommendations.

---

• ⚠️ Specialist only — orthopaedic surgeon + ID specialist.
• ⛔ Never use rifampicin as monotherapy.
• Cephalexin for chronic suppression has an adherence advantage: can be taken with food, BD-TDS dosing feasible.
• Evidence basis:Moderate — IDSA PJI Guidelines 2013.

---

PAEDIATRIC DOSING (Specialist Only)

---

• Safety monitoring: Monitor for allergic reactions (rash, urticaria — rare anaphylaxis), IV site phlebitis (less common than with antistaphylococcal penicillins), diarrhoea. Renal function monitoring if prolonged course or concurrent nephrotoxic drugs.
• Minimum age: No specific lower age limit — used from the neonatal period onwards (see neonatal section below).
• Formulation suitability:
• • ⛔ No oral formulation of cefazolin exists. For oral step-down in children: use cephalexin suspension (125 mg/5 mL, 250 mg/5 mL — ✅ NLEM, widely available in India, pleasant flavour, can be taken with food). This is the most commonly prescribed oral first-generation cephalosporin for children in India.
  • IV/IM powder for injection vials (250 mg, 500 mg, 1 g) can be reconstituted for weight-based paediatric dosing.
• Palatability: Not relevant for IV/IM administration. Cephalexin suspension (oral step-down) has acceptable palatability — strawberry/tutti-frutti flavour in most Indian brands.
• Age-specific PK: Neonates: prolonged half-life (~3–5 hours) due to immature renal function — extended dosing intervals. Infants >1 month: clearance per kg approaches adult values; standard weight-based dosing.
• Adolescent transition: Children ≥12 years or ≥40 kg → use adult dosing (1–2 g IV q8h).

---

• Per dose: 2 g (same as adult)
• Per day: 6 g for standard treatment; 8 g in exceptional circumstances

---

Primary Indications — Paediatric (Approved / Standard)

---

• Same principles as adult surgical prophylaxis — timing, re-dosing, and duration limits apply equally to paediatric surgery.
• ✅ NLEM: Cefazolin IS NLEM.
• Common paediatric surgical prophylaxis scenarios: appendicectomy, hernia repair, orthopaedic hardware insertion, VP shunt placement, cardiac surgery.
• For appendicectomy and bowel surgery in children: add metronidazole (7.5 mg/kg IV) for anaerobic coverage.
• IAP Guidelines; AIIMS Paediatric Surgery Protocol.

---

• ℹ️ Paediatric osteomyelitis has the strongest evidence for early IV-to-oral switch — Peltola et al. RCTs (2010, 2012) validated 3–5 days IV followed by high-dose oral therapy.
• Oral step-down to cephalexin suspension — ✅ NLEM, widely available, well-tolerated, can be given with food.
• ⚠️ India-specific: always consider TB osteomyelitis in differential.
• IAP Guidelines; Peltola et al. paediatric RCTs.
• NLEM: ✅ Both cefazolin and cephalexin are NLEM.

---

• Joint drainage MANDATORY.
• Same early switch principles as osteomyelitis.
• NLEM: ✅.

---

• Obtain urine C&S (clean catch or catheter specimen) BEFORE starting — MANDATORY.
• ⚠️ ESBL prevalence in paediatric urinary isolates is rising in India (>30% in some centres) — cefazolin may be unreliable for empiric UTI therapy. Local antibiogram guidance essential.
• All children with first febrile UTI: renal ultrasound recommended. DMSA/MCU per IAP Paediatric Nephrology guidelines.
• NLEM: ✅.
• IAP Guidelines for UTI in Children.

---

• For extensive cellulitis, post-I&D of large abscess with systemic toxicity, periorbital cellulitis (preseptal — mild-moderate).
• ⛔ Does NOT cover MRSA — culture when possible.
• Oral step-down: cephalexin suspension. NLEM: ✅.

---

Neonatal Dosing

1. ⛔ Cefazolin is NOT first-line for empiric neonatal sepsis. Standard empiric EONS therapy per NNF India / AIIMS: Ampicillin + Gentamicin. Cefazolin has no coverage for Listeria monocytogenes (a key EONS pathogen) — ⛔ ALL cephalosporins are intrinsically resistant to Listeria.
2. When cefazolin IS used in neonates:
3. • Surgical prophylaxis for neonatal surgery (cardiac, abdominal, orthopaedic)
   • Targeted therapy for MSSA infections confirmed on culture
   • UTI treatment when urine culture confirms a susceptible organism
   • Always as culture-guided targeted therapy in neonates
4. ⛔ No oral formulation — IV throughout neonatal course. Oral step-down (to cephalexin suspension) only when on full enteral feeds, clinically stable, and post-neonatal period.

---

Secondary Indications — Paediatric (Off-label, if any)

---

---

• SSSS caused by exfoliative toxins of S. aureus (phage group II) — primarily neonates and children <5 years.
• Cefazolin IV is a reasonable first-line alternative to IV cloxacillin for SSSS — q8h dosing advantage.
• Supportive care: IV fluids, skin care, pain management.
• Evidence basis:Weak — expert opinion, textbook recommendations. No RCTs comparing cefazolin to cloxacillin for SSSS specifically.
• IAP Guidelines; API Textbook.

---

• Empiric therapy for periorbital cellulitis should cover staphylococci, streptococci, AND H. influenzae — amoxicillin-clavulanate or ampicillin-sulbactam preferred for empiric coverage.
• Cefazolin provides staphylococcal + streptococcal + limited gram-negative coverage — may be adequate for culture-confirmed MSSA preseptal cellulitis.
• ⚠️ Differentiate preseptal from orbital cellulitis — orbital requires CT + broader coverage + ophthalmology/ENT referral.
• Evidence basis:Weak — expert opinion.

---

---

MISSED DOSE / DELAYED DOSE GUIDANCE

---

• IV doses are administered on a fixed q8h schedule (e.g., 06:00, 14:00, 22:00 — three doses per day).
• If a dose is delayed:
• • Delayed <4 hours: Administer immediately. Re-space subsequent doses to maintain q8h intervals from the delayed dose.
  • Delayed >4 hours: Administer immediately. Inform the treating physician. Resume regular q8h schedule from the delayed dose timing.
  • ⚠️ For critically ill / bacteraemic / endocarditis patients: While cefazolin’s longer half-life provides more tolerance for delays than shorter-half-life penicillins, timely dosing remains important. If delay exceeds 2 hours, inform the treating physician.
• Never skip a dose entirely without physician instruction — give the delayed dose and re-adjust the schedule.

• If delayed <3 hours: Administer immediately. Re-space.
• If delayed >3 hours: Administer immediately, inform physician, resume q6h from delayed dose.

• If delayed <6 hours: Administer immediately. Resume q12h schedule.
• If delayed >6 hours: Administer immediately, inform physician, resume schedule.

• Pre-operative dose NOT given: If the anaesthetist/surgeon realises the prophylactic dose was not administered before incision:
• • Before incision (any time in the 60-minute window): Give immediately — still effective.
  • After incision but <60 minutes post-incision: Give NOW — late prophylaxis provides some benefit, though suboptimal.
  • >60 minutes post-incision: Give the dose anyway (for ongoing tissue protection during surgery) — but the prophylactic window has been significantly compromised for the initial contamination phase. Document the timing error.
• Intraoperative re-dosing missed: If the procedure exceeds 4 hours and re-dosing was not given:
• • Administer the re-dose as soon as recognised. Tissue levels will have fallen below optimal but residual activity persists (longer half-life helps).
  • If recognised only at the end of surgery: give the dose as a post-operative dose.

• Cefazolin’s q8h dosing makes it one of the most OPAT-feasible antibiotics (only 3 injections/day).
• Typical OPAT schedule: morning (e.g., 07:00), afternoon (e.g., 15:00), night (e.g., 23:00).
• If patient/caregiver misses a dose at home:
• • Give as soon as remembered. Re-space subsequent doses.
  • If >4 hours late: give immediately, notify the OPAT team, resume regular schedule.
  • ⛔ Never skip a dose — all three daily doses are important for maintaining therapeutic levels.
  • If two or more consecutive doses missed: notify OPAT team immediately — reassessment needed (repeat blood cultures for bacteraemia, clinical evaluation for relapse).

• Cefazolin is used as a finite-duration antibiotic course — not chronic therapy.
• If 2 or more consecutive doses are missed (≥16+ hours without drug in a q8h regimen):
• • Sub-therapeutic levels will have been present for a significant period.
  • Resume immediately at full dose — no re-titration required.
  • Inform the treating physician/ID specialist.
  • For bacteraemia/endocarditis: repeat blood cultures to confirm ongoing clearance.
  • Consider whether total treatment duration needs to be extended by the missed days.
• No withdrawal or rebound effects.
• No immunogenicity risk (not a biologic).

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

• Hospital pharmacy can pre-prepare multiple doses in advance (batch reconstitution) — reduces bedside preparation time and risk of reconstitution errors.
• OPAT feasibility: patients/caregivers can be given pre-prepared syringes or mini-bags stored in the home refrigerator — valid for up to 10 days. This dramatically simplifies home IV therapy logistics.
• In Indian hospitals with limited nursing staff: pre-prepared doses reduce the need for each nurse to reconstitute at every dosing time.
• ⚠️ Indian hot-climate caveat: The 24-hour room temperature stability is based on 25°C. In Indian summer (ambient 35–45°C in many regions), stability may be shorter. If ambient temperature exceeds 30°C: use within 12 hours at room temperature, or store reconstituted solution in a refrigerator (where available) and bring to room temperature just before infusion.

• Standard cefazolin vials are single-use (no preservative).
• ⛔ Do NOT re-puncture reconstituted vials repeatedly — contamination risk.
• If multiple paediatric doses are drawn from a single reconstituted vial (economical practice in resource-limited settings): use within 24 hours if stored at room temperature (≤25°C), or 48 hours if refrigerated. Document the time of reconstitution on the vial. Use strict aseptic technique with each withdrawal. ⚠️ This practice, while common in Indian hospitals, carries contamination risk — single-dose vials are preferred for neonates and immunocompromised patients.

• Dose = 25 mg/kg × 20 kg = 500 mg per dose
• Using 1 g vial reconstituted in 2.5 mL SWFI → concentration ~330 mg/mL
• Volume to draw = 500 mg ÷ 330 mg/mL = ~1.5 mL
• Dilute in 25–50 mL Normal Saline; infuse over 15–30 minutes.
• Or: administer 1.5 mL as slow IV push over 3–5 minutes.

• Dose = 25 mg/kg × 3 kg = 75 mg per dose
• Using 250 mg vial reconstituted in 2 mL SWFI → concentration ~113 mg/mL
• Volume to draw = 75 mg ÷ 113 mg/mL = ~0.66 mL
• Dilute in 5–10 mL Normal Saline; infuse over 15–30 minutes using syringe pump.
• ⚠️ Use a 1 mL syringe for accuracy in neonatal dosing.

• Weight ≥120 kg → prophylactic dose = 3 g IV
• Using 2 g vial (reconstituted in 5 mL) + 1 g vial (reconstituted in 2.5 mL)
• Total volume: ~6 mL + ~3 mL = ~9 mL of reconstituted solution
• Dilute in 50–100 mL NS; infuse over 15–30 minutes (or administer as slow IV push over 5 minutes)
• Administer within 60 minutes before skin incision. Re-dose at 4 hours if procedure ongoing.

---

---

---

---

• Dry powder vials: ✅ NO cold-chain required. Stable at room temperature. This is a major logistical advantage for Indian distribution — cefazolin can be supplied to PHCs, CHCs, and remote centres without cold-chain infrastructure.
• Reconstituted solution: refrigeration extends stability to 10 days — useful for batch preparation and OPAT.
• No special transport cold-chain requirements for the dry powder.

---

RENAL ADJUSTMENT

---

• ARC is defined as measured CrCl >130 mL/min (by 8- or 24-hour urine creatinine clearance).
• Common in: young adults (18–50 years), polytrauma, burns, sepsis without organ failure, early septic shock (before renal impairment).
• Impact on cefazolin: ARC dramatically increases cefazolin renal clearance → subtherapeutic serum levels with standard q8h dosing → risk of treatment failure, especially for organisms with MICs at the upper end of the susceptible range.
• ⚠️ This is a REAL clinical problem — PK studies in ICU patients with ARC show that standard cefazolin 2 g q8h achieves target %fT > MIC in only ~60–70% of patients with ARC for organisms with MIC of 2 mg/L (the CLSI susceptibility breakpoint for MSSA).

1. Increase dosing frequency: Use 2 g IV q6h (instead of q8h) — 4 doses/day instead of 3. This increases %fT > MIC target attainment to >90%.
2. Continuous infusion: Total daily dose (e.g., 6–8 g) dissolved in NS, infused continuously over 24 hours via infusion pump — maximises %fT > MIC (approaching 100%). Stability supports 24-hour infusion in NS. Specialist ICU protocol only. Some Indian tertiary ICUs (AIIMS, CMC Vellore, PGIMER) have adopted this approach for beta-lactam optimisation.
3. Therapeutic drug monitoring (TDM): If available — measure cefazolin trough levels. Target: free cefazolin concentration above the organism’s MIC throughout the dosing interval. Not routinely available in India.

• Cefazolin crystalluria is exceedingly rare at standard doses — unlike high-dose ampicillin or sulfonamides.
• No specific crystalluria prevention measures are needed.
• Standard hydration during IV therapy is sufficient.

---

HEPATIC ADJUSTMENT

---

• Chronic liver disease (alcohol-related, HBV, HCV) is common
• Anti-TB drug-induced hepatotoxicity is frequent — adding another hepatotoxic drug (oxacillin, flucloxacillin) to a patient with ATT-related DILI is risky
• Fatty liver disease/NASH is increasingly prevalent

• Anti-TB drugs (rifampicin, isoniazid, pyrazinamide) — no additive liver risk from cefazolin
• Methotrexate — no hepatic interaction from cefazolin (though renal interaction may occur — see Drug Interactions)
• Valproate — no hepatic interaction
• Antiretrovirals — no hepatic interaction
• Paracetamol — no hepatic interaction

---

CONTRAINDICATIONS

---

---

• Rationale: Risk of recurrent anaphylaxis — potentially fatal. Includes history of angioedema, severe urticaria with hypotension, laryngospasm, or bronchospasm with any cephalosporin.
• ℹ️ Mild, non-IgE-mediated reactions to other cephalosporins (delayed maculopapular rash) are NOT absolute contraindications to cefazolin — but administer with caution and monitoring.

1. Penicillin allergy is commonly reported (many mislabelled — ~80–90% are not truly allergic)
2. Cefazolin is the standard surgical prophylaxis — a patient labelled ”penicillin-allergic“ presenting for surgery creates a decision point
3. MSSA bacteraemia/endocarditis in a penicillin-allergic patient — cefazolin is the best non-penicillin alternative

---

• Rationale: Documented IgE-mediated anaphylaxis to cefazolin itself — re-exposure carries high recurrence risk.
• ⛔ Avoid cefazolin. Other cephalosporins with different R1 side chains MAY be usable after formal allergy evaluation (cefazolin has a unique tetrazole side chain).
• Use vancomycin or clindamycin for surgical prophylaxis; vancomycin or daptomycin for MSSA treatment.

---

• Rationale: This contraindication is well-established for ceftriaxone (fatal ceftriaxone-calcium precipitates in neonatal lungs and kidneys). Cefazolin does NOT share this specific chemistry with ceftriaxone, and cefazolin-calcium precipitation has NOT been reported. However, as a precautionary measure in neonates — some institutions extend this caution to all IV cephalosporins. In practice: cefazolin can be safely administered to neonates receiving calcium-containing fluids, PROVIDED they are given through separate IV lines or the line is flushed with NS between drugs. This is standard practice, not a true contraindication for cefazolin specifically.
• ℹ️ This is a near-absolute contraindication specific to ceftriaxone, NOT cefazolin. Listed here for completeness as it is sometimes erroneously applied to cefazolin.

---

CAUTIONS

---

---

• ⚠️ THE most important caution for cefazolin — distinguishes it from nafcillin (hepatic clearance, no renal adjustment) and from most clinical scenarios with cloxacillin (which generally does not require formal adjustment).
• Cefazolin is ~80–90% renally eliminated. In significant renal impairment (CrCl <35 mL/min), half-life is markedly prolonged → accumulation at standard intervals → risk of adverse effects (though toxicity is uncommon due to wide therapeutic index).
• Monitoring: Serum creatinine at baseline and periodically during therapy. Calculate CrCl (Cockcroft-Gault) before prescribing. Adjust dosing interval per Renal Adjustment table (Part 3 above).
• ⚠️ India-specific: Many elderly Indian patients have undiagnosed CKD. A ”normal“ serum creatinine in a thin, elderly patient may correspond to CrCl of only 30–40 mL/min. ALWAYS calculate CrCl — do not rely on serum creatinine alone.

---

• Cefazolin is significantly removed by HD (~35–60% per session). Post-HD supplemental dosing is MANDATORY. Failure to supplement leads to subtherapeutic levels for the post-HD period.
• Action: Give supplemental dose (500 mg–1 g) after each HD session. See Renal Adjustment table.

---

• In young ICU patients with ARC (CrCl >130 mL/min): standard q8h dosing may be subtherapeutic.
• Action: Use q6h dosing or continuous infusion in ARC patients with serious MSSA infections. See ARC section above.

---

• Cross-reactivity rate ~2–5%. For non-severe penicillin allergy: cefazolin can be used with monitored first dose. For severe penicillin anaphylaxis: formal allergy evaluation or alternative agent (vancomycin). See detailed algorithm under Contraindications.

---

• All antibiotics carry CDI risk. Cefazolin’s narrow spectrum (first-generation cephalosporin) confers LOWER CDI risk than broad-spectrum cephalosporins (third-generation — ceftriaxone, cefotaxime — are among the highest-risk antibiotics for CDI). However, CDI can still occur.
• ⚠️ India-specific: The risk is amplified in: elderly patients, hospitalised patients, those with recent prior antibiotic exposure, concurrent PPI use, prolonged antibiotic courses.
• Monitoring: Instruct nursing staff and patients to report new-onset watery diarrhoea (≥3 loose stools/day). Test for C. difficile toxin if suspected.
• Action: Stop cefazolin if CDI confirmed. Treat CDI per standard protocol (oral vancomycin 125 mg QDS × 10 days).

---

• ⛔ Continuing cefazolin prophylaxis beyond 24 hours post-operatively is the single most common antibiotic stewardship violation in Indian surgical practice. No evidence supports prophylaxis >24 hours for clean/clean-contaminated procedures.
• Action: Prescribe prophylaxis as a single pre-operative dose ± up to 24 hours post-operatively. Document stop date/time on the prescription. Active stewardship programmes should audit prophylaxis duration.

---

• ⚠️ In Indian hospital settings, ESBL prevalence among E. coli and Klebsiella is 40–70%. Cefazolin is COMPLETELY INEFFECTIVE against ESBL producers. Do NOT rely on cefazolin for empiric gram-negative therapy in nosocomial infections without culture guidance.
• Action: For empiric nosocomial gram-negative coverage: use piperacillin-tazobactam, ceftriaxone (if local antibiogram supports), or carbapenems — NOT cefazolin.

---

---

• Oral candidiasis, vaginal candidiasis, antibiotic-associated diarrhoea (non-CDI) — standard antibiotic caution. Cefazolin’s narrow spectrum confers lower superinfection risk than broad-spectrum agents.

---

• Very high-dose cephalosporins (particularly in renal impairment with drug accumulation) can rarely lower seizure threshold. Risk with cefazolin at standard doses is very low. Risk is primarily with third-generation cephalosporins (cefepime) at very high doses in renal failure.
• Action: Standard doses of cefazolin are safe in patients with seizure history. If using high doses in renal impairment: adjust per renal table.

---

• Neonatal renal immaturity prolongs cefazolin half-life (~3–5 hours). Extended dosing intervals (q8–12h) are mandatory. NICU supervision required.
• ⛔ Cefazolin does NOT cover Listeria — never use as sole empiric therapy for neonatal meningitis.

---

• False-positive urine glucose: With copper-reduction methods (Benedict’s test, Clinitest). Enzymatic methods (glucose oxidase — Diastix, glucometer strips) are NOT affected.
• False-positive direct Coombs test (DAT): Can cause positive DAT — may complicate blood bank crossmatching. Clinical haemolytic anaemia is very rare.
• No interference with enzymatic creatinine assays (unlike some older cephalosporins with Jaffe method).

---

• Cefazolin sodium contains approximately 2.1 mEq sodium per gram. At maximum dosing (8 g/day → ~17 mEq sodium/day). In sodium-restricted patients: factor into daily sodium budget. Generally clinically insignificant at standard doses.

---

• Probenecid inhibits renal tubular secretion of cefazolin → increased serum levels and prolonged half-life. Clinically insignificant in most cases. Monitor if concurrent use is prolonged.

---

• IM cefazolin is moderately painful. Reconstitution with 0.5% lidocaine (lignocaine) reduces pain significantly and is recommended. Do NOT use lidocaine-reconstituted cefazolin for IV administration.

---

• The ”inoculum effect“ (see Part 1) means that in vitro MICs of cefazolin against some MSSA strains increase at high bacterial inocula. While the FIRST trial (2023) showed non-inferior outcomes overall, some experts exercise caution with cefazolin for: large vegetations (>10 mm), prosthetic valve endocarditis, or MSSA isolates with documented high inoculum-effect MICs. This is a clinical judgment issue, not a contraindication — discuss with ID specialist.

---

• ⛔ Cefazolin has POOR CSF penetration (~1–3% of serum levels even with inflamed meninges). Do NOT use for meningitis (MSSA or any pathogen). If MSSA meningitis is diagnosed: use IV cloxacillin/flucloxacillin (slightly better CSF penetration — still suboptimal) or consider IV vancomycin (adequate CSF levels with meningeal inflammation) or specialist-guided alternatives.

---

PREGNANCY

---

• Mother: Standard adverse effect monitoring. Renal function (pregnancy increases GFR — relevant for cefazolin clearance but standard doses remain adequate). No LFT monitoring needed (zero hepatic metabolism/hepatotoxicity).
• Fetus/Neonate: No specific fetal monitoring required. Post-delivery observation of neonate is routine — no additional monitoring specifically for cefazolin exposure.
• ℹ️ For GBS IAP: neonatal GBS monitoring per standard institutional protocol regardless of the specific antibiotic used.

---

LACTATION

---

• Loose stools or mild diarrhoea (most common — usually mild, transient)
• Nappy/diaper rash
• Oral thrush (white patches in mouth — treat with nystatin oral drops)
• Skin rash (very rare)
• Feeding difficulties or irritability (very rare)

• ℹ️ Cefazolin is administered IV in a hospital setting — dosing schedule is fixed by nursing staff. Breastfeeding may continue at any time relative to the IV dose. Given the very low RID (~0.8–1.5%), timing is NOT critical.
• For postpartum patients receiving cefazolin for C-section prophylaxis (typically 1–3 doses within 24 hours): breastfeeding should be initiated as per standard practice — no delay needed.

---

ELDERLY

---

---

MAJOR DRUG INTERACTIONS

---

• ✅ Zero hepatic metabolism (no CYP substrate, inhibitor, or inducer)
• ✅ No CYP3A4 induction (unlike nafcillin, dicloxacillin)
• ✅ No significant drug transporter interactions (P-gp, OATP, OAT, OCT, BCRP, MATE)
• ✅ No protein-binding displacement of clinical significance

---

---

MODERATE DRUG INTERACTIONS

---

---

COMMON ADVERSE EFFECTS

---

---

SERIOUS ADVERSE EFFECTS

---

---

MONITORING REQUIREMENTS

---

---

---

---

• ❌ LFTs NOT needed (unlike oxacillin — which requires weekly LFTs due to ~5–15% hepatotoxicity)
• ❌ No CYP-related drug level monitoring (unlike nafcillin/dicloxacillin — which require monitoring of warfarin INR for CYP3A4-mediated interaction, cyclosporine/tacrolimus troughs)
• ❌ No TDM (wide therapeutic index; TDM not routinely available or needed)

---

• ICU patients with augmented renal clearance (ARC) — to confirm adequate drug exposure when standard dosing may be subtherapeutic
• Patients on continuous infusion cefazolin — to verify target free drug concentration above MIC throughout the infusion period
• Morbidly obese patients — to verify adequate tissue concentrations
• In practice: TDM for cefazolin is NOT available as a routine service at any Indian hospital. Clinical monitoring (blood culture clearance, CRP, clinical response) serves as the surrogate.

---

• Surgical prophylaxis (single dose or 24 hours): No ongoing monitoring needed after the prophylactic dose(s). No post-treatment monitoring.
• Short treatment courses (5–10 days for SSTIs/UTIs): Check creatinine at day 5–7 if baseline was abnormal. No ongoing monitoring after course completion.
• Prolonged courses (>14 days — bacteraemia, endocarditis, osteomyelitis): Continue weekly creatinine and biweekly CBC for 1 week after completing therapy. For endocarditis: clinical + blood culture follow-up at 2–6 weeks post-treatment (relapse surveillance).

---

PATIENT COUNSELLING

---

---

• Prevent infection after surgery (given as an injection before the operation)
• Treat serious infections of the blood, heart, bones, joints, skin, or urinary system

---

• A drip into your vein (IV) — usually over 15–30 minutes, three times a day (every 8 hours). This is less frequent than some other similar antibiotics that need to be given 4–6 times a day — so you will have more rest between doses.
• An injection into the muscle (IM) — if a vein drip is not possible. This may be slightly painful at the injection site.
• Before surgery — a single dose given as a drip about 30–60 minutes before the operation begins. You may not even notice it — the anaesthesia team gives it while preparing you for surgery."

---

---

• Mild pain or redness where the drip enters your vein — this is common with any IV medicine. Tell the nurse so they can check or change the drip site.
• Mild loose motions — drink plenty of water. Eating curd (dahi/yoghurt) may help.
• Mild nausea — usually settles quickly.

---

• Skin rash with blisters, peeling, or sores in the mouth or eyes — rare but serious
• Swelling of face, lips, tongue, or throat; difficulty breathing — this may be a severe allergic reaction — this is an emergency
• Severe watery or bloody diarrhoea with stomach cramps and fever — even after finishing the medicine
• Very little urine, swelling of feet, or blood in urine — may mean the medicine is affecting your kidneys (very rare with this medicine)
• The infection getting WORSE (more pain, more redness, fever returning after improving)"

---

• ⛔ Do NOT stop the medicine early without your doctor’s instruction — even if you feel better.
• If you are on blood-thinning tablets (warfarin/Acitrom), your doctor will monitor your blood tests (INR) — this medicine can mildly affect how your blood thinner works.
• Alcohol: No absolute ban, but avoiding alcohol during illness and treatment is advisable.

---

• ”If pre-prepared syringes are kept at home, store them in the refrigerator (2–8°C). They can be used for up to 10 days if refrigerated. Take out of the fridge 30 minutes before the injection and let it come to room temperature before injecting — cold injections are more painful.“

---

• Surgery prevention: Usually just 1 dose before the operation (sometimes a few more doses for up to 24 hours after surgery). ⚠️ If you are still receiving this injection days after surgery and feel well, ask your doctor whether it can be stopped — prolonged use after surgery is usually not needed.
• Skin / urinary infections: Usually 5–14 days. Your doctor may switch you to a tablet medicine (cephalexin) once you improve.
• Blood / heart / bone infections:2–6 weeks. Your doctor will tell you exactly how long."

---

• You can take it with or without food — this makes it easier than some other antibiotics.
• Take it 3–4 times a day (every 6–8 hours) as prescribed.
• Complete the full course even if you feel completely better.
• If you miss a dose: take it as soon as you remember, unless the next dose is due in less than 4 hours — then skip the missed dose. Never take a double dose."

---

• At the scheduled follow-up date — for blood tests and check-up
• If the infection returns (fever, redness, pain, swelling at the infection site)
• If you develop severe diarrhoea (can occur up to 2 months after antibiotics)
• For blood infections / heart valve infections: your doctor will schedule specific follow-up visits — do not miss these"

---

---

• The patient is receiving an injection antibiotic — the nurse will give it at scheduled times.
• Watch for and report: skin rash, difficulty breathing, severe diarrhoea, reduced urine, swelling, or the patient becoming more unwell.
• When the patient is discharged on oral tablets (cephalexin): help them take the tablets on time and complete the full course.
• Attend all follow-up appointments.
• If pre-prepared injections are sent home (OPAT): keep them in the refrigerator and follow the nurse’s instructions on how and when to give them."

---

---

BRANDS AVAILABLE IN INDIA

---

---

---

PRICE RANGE (INR)

---

1. Cefazolin and cloxacillin are similarly priced at government/generic rates — both are NLEM and DPCO-controlled.
2. Cefazolin’s q8h dosing reduces TOTAL treatment costs beyond the drug itself: fewer IV consumables (syringes, tubing, NS bags), less nursing time (3 doses vs 4–6), fewer IV site changes (lower phlebitis), potentially shorter hospitalisation (OPAT feasibility with q8h IM cefazolin vs impractical q4h cloxacillin OPAT).
3. The true cost advantage of cefazolin is in REDUCED HEALTHCARE SYSTEM COSTS — not just per-vial pricing. A drug that requires 3 injections/day instead of 6 saves approximately 50% of nursing preparation time, 50% of consumables, and 50% of IV-site-related complications — these savings compound over a 2–6 week treatment course.

---

CLINICAL PEARLS

---

---

• Error 1: Using 1 g instead of 2 g — a 1 g dose produces suboptimal tissue concentrations in patients >60 kg. Use 2 g as the standard adult dose (3 g for ≥120 kg). Updated ASHP/IDSA/SIS guidelines (2013, adopted by AIIMS) recommend 2 g.
• Error 2: Giving AFTER incision — many Indian surgeons request antibiotics only after the operation begins or after cord clamping (for C-section). The drug MUST be in the tissues BEFORE bacterial contamination occurs. Administer within 60 minutes before skin incision.
• Error 3: Continuing prophylaxis for 3–7 days — no evidence supports prophylaxis >24 hours for clean/clean-contaminated surgery. STOP at 24 hours. This is the single most impactful antimicrobial stewardship intervention in Indian surgical practice.

---

---

---

---

---

VERSION

---

REFERENCES

---

1. CDSCO Product Insert — Reflin (Cefazolin Sodium for Injection), Sun Pharma, India. Referenced for: approved indications, formulation details, reconstitution/stability data, Indian labelling.
2. CDSCO Product Insert — Cefazol (Cefazolin Sodium for Injection), Biochem Pharmaceutical, India. Referenced for: dosing, administration details.
3. Indian Pharmacopoeia (IP) 2022, Indian Pharmacopoeia Commission, Ghaziabad. Monograph on Cefazolin Sodium for Injection.
4. National List of Essential Medicines (NLEM) India, 2022. Ministry of Health and Family Welfare. Section: Anti-infective Medicines — Antibacterials (Cephalosporins). ✅ Cefazolin Injection 1 g IS listed. ✅ Cephalexin Capsule 250 mg, 500 mg IS listed.
5. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter: Cephalosporins and Other Beta-Lactam Antibiotics. Used for: pharmacokinetics (half-life, protein binding, renal elimination, free drug fraction analysis), spectrum of activity, inoculum effect discussion, drug interaction profile, comparative PK analysis.
6. Harrison’s Principles of Internal Medicine, 21st Edition (2022). Chapters on: Treatment of Bacterial Infections; Staphylococcal Infections; Infective Endocarditis; Osteomyelitis; Skin and Soft Tissue Infections; Urinary Tract Infections; Surgical Prophylaxis.

1. API (Association of Physicians of India) Textbook of Medicine, 11th Edition (2019). Chapters on: Antimicrobial Therapy; Staphylococcal Infections; Endocarditis; Osteomyelitis; Surgical Infections; UTI.
2. ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes, 2nd Edition (2019). Referenced for: empiric antibiotic recommendations, MRSA/ESBL prevalence data, antimicrobial stewardship, surgical prophylaxis.
3. AIIMS Empiric Antibiotic Guidelines / Antibiotic Policy / Surgical Prophylaxis Protocol. All India Institute of Medical Sciences, New Delhi. Referenced for: cefazolin as first-line surgical prophylaxis, weight-based prophylactic dosing, 24-hour prophylaxis duration policy, MSSA treatment protocols.
4. IAP (Indian Academy of Pediatrics) Guidelines. Referenced for: paediatric surgical prophylaxis, paediatric osteomyelitis (early oral switch), paediatric UTI management.
5. NNF (National Neonatology Forum) India — Clinical Practice Guidelines. Referenced for: neonatal dosing intervals, neonatal sepsis empiric regimens (ampicillin + gentamicin — NOT cefazolin as first-line), Listeria coverage gap.
6. FOGSI (Federation of Obstetric and Gynaecological Societies of India) Guidelines. Referenced for: caesarean section prophylaxis (cefazolin first-line), GBS IAP in penicillin-allergic mothers.
7. CSI (Cardiological Society of India) Recommendations. Referenced for: endocarditis management.
8. NCDC (National Centre for Disease Control) — Infection Control Guidelines. Referenced for: surgical prophylaxis protocols, antimicrobial stewardship.
9. IADVL (Indian Association of Dermatologists, Venereologists and Leprologists) Guidelines. Referenced for: SSTI management.
10. Indian Society of Nephrology / ISPD (International Society for Peritoneal Dialysis) Guidelines. Referenced for: PD peritonitis — intraperitoneal cefazolin dosing.

1. FIRST Trial: Tong SYC, Lye DC, Yahav D, et al. ”Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, and Treatment Failure in Patients With MSSA Bacteremia: The FIRST Randomized Clinical Trial.“ JAMA. 2023;329(9):713–722. ⚠️ THE landmark trial validating cefazolin as non-inferior to antistaphylococcal penicillins for MSSA bacteraemia. Referenced extensively throughout this monograph.
2. POET Trial: Iversen K, Ihlemann N, Gill SU, et al. ”Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.“ N Engl J Med. 2019;380(5):415–424. Referenced for: oral step-down endocarditis (cephalexin as step-down from cefazolin).
3. OVIVA Trial: Li HK, Rombach I, Zamber R, et al. ”Oral versus Intravenous Antibiotics for Bone and Joint Infection.“ N Engl J Med. 2019;380(5):425–436. Referenced for: oral step-down osteomyelitis.
4. Peltola H, Pääkkönen M, et al. ”Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood.“ Pediatr Infect Dis J. 2010;29(12):1123–1128. Referenced for: early oral switch in paediatric osteomyelitis.
5. ASHP/IDSA/SIS Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery (2013). Bratzler DW, Dellinger EP, Olsen KM, et al. Am J Health-Syst Pharm. 2013;70:195–283. Referenced for: surgical prophylaxis weight-based dosing (2 g standard, 3 g for ≥120 kg), re-dosing intervals, duration limits.
6. AHA/IDSA Guidelines for Infective Endocarditis (2015, with updates). Referenced for: endocarditis treatment regimens.
7. IDSA MRSA Guidelines (2011). Referenced for: MSSA bacteraemia management, echocardiography, ID consultation.
8. IDSA PJI Guidelines (2013). Osmon DR et al. Clin Infect Dis. Referenced for: prosthetic joint infection management.
9. ESC Guidelines for Infective Endocarditis (2023). European Society of Cardiology. Referenced for: cefazolin inclusion as accepted MSSA endocarditis treatment option.
10. ISPD Peritonitis Guidelines (2022). Referenced for: intraperitoneal cefazolin dosing for PD peritonitis.

1. NPPA (National Pharmaceutical Pricing Authority) / DPCO Data. Referenced for: pricing, NLEM ceiling prices.
2. Jan Aushadhi (PMBJP) Product Catalogue, 2024–2025. Referenced for: cefazolin and cephalexin availability at Jan Aushadhi Kendras.
3. CDSCO NSQ Alerts Database — www.cdsco.gov.in. Checked for quality alerts.
4. PvPI (Pharmacovigilance Programme of India). Referenced for: ADR reporting protocol.
5. KD Tripathi, Essentials of Medical Pharmacology, 8th Edition (2019). Chapter: Beta-Lactam Antibiotics — Cephalosporins. Referenced for: Indian pharmacology context, inoculum effect discussion.
6. CLSI M100 — Performance Standards for Antimicrobial Susceptibility Testing (2024 Edition). Referenced for: MSSA/MRSA breakpoints, cefazolin susceptibility interpretation.

---